Olema Reports Promising Phase 1b/2 Data for Palazestrant Plus Ribociclib in Advanced Breast Cancer

Reuters

2025/10/18

Olema Reports Promising Phase 1b/2 Data for Palazestrant Plus Ribociclib in Advanced Breast Cancer

Olema Pharmaceuticals Inc. has announced updated data from a Phase 1b/2 clinical study evaluating palazestrant (OP-1250) in combination with ribociclib for patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. The results, which will be presented at the European Society for Medical Oncology (ESMO) Congress 2025 on October 20, showed that the combination demonstrated activity across all dose cohorts and subgroups. The median progression-free survival $(PFS)$ was 15.5 months in the 120 mg palazestrant cohort overall. Among patients previously treated with CDK4/6 inhibitors, median PFS was 9.2 months for those with ESR1 wild-type tumors and 13.8 months for those with ESR1 mutant tumors. The regimen continued to show favorable tolerability and a safety profile consistent with known profiles of the individual drugs. These findings support the ongoing Phase 3 OPERA-02 trial, which is assessing the combination as a frontline therapy in advanced or metastatic breast cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Olema Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9547706-en) on October 18, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2576095090"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2576095090\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2576095090?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-18 15:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2576095090","market":"fut","top_or_hot":-1,"title":"Olema Reports Promising Phase 1b/2 Data for Palazestrant Plus Ribociclib in Advanced Breast Cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Olema Reports Promising Phase 1b/2 Data for Palazestrant Plus Ribociclib in Advanced Breast Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Olema Pharmaceuticals Inc. has announced updated data from a Phase 1b/2 clinical study evaluating palazestrant (OP-1250) in combination with ribociclib for patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. The results, which will be presented at the European Society for Medical Oncology (ESMO) Congress 2025 on October 20, showed that the combination demonstrated activity across all dose cohorts and subgroups. The median progression-free survival <a href=\"https://laohu8.com/S/PFS\">$(PFS)$</a> was 15.5 months in the 120 mg palazestrant cohort overall. Among patients previously treated with CDK4/6 inhibitors, median PFS was 9.2 months for those with ESR1 wild-type tumors and 13.8 months for those with ESR1 mutant tumors. The regimen continued to show favorable tolerability and a safety profile consistent with known profiles of the individual drugs. These findings support the ongoing Phase 3 OPERA-02 trial, which is assessing the combination as a frontline therapy in advanced or metastatic breast cancer.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Olema Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9547706-en) on October 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Olema Reports Promising Phase 1b/2 Data for Palazestrant Plus Ribociclib in Advanced Breast Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOlema Reports Promising Phase 1b/2 Data for Palazestrant Plus Ribociclib in Advanced Breast Cancer\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-10-18 15:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Olema Reports Promising Phase 1b/2 Data for Palazestrant Plus Ribociclib in Advanced Breast Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Olema Pharmaceuticals Inc. has announced updated data from a Phase 1b/2 clinical study evaluating palazestrant (OP-1250) in combination with ribociclib for patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. The results, which will be presented at the European Society for Medical Oncology (ESMO) Congress 2025 on October 20, showed that the combination demonstrated activity across all dose cohorts and subgroups. The median progression-free survival <a href=\"https://laohu8.com/S/PFS\">$(PFS)$</a> was 15.5 months in the 120 mg palazestrant cohort overall. Among patients previously treated with CDK4/6 inhibitors, median PFS was 9.2 months for those with ESR1 wild-type tumors and 13.8 months for those with ESR1 mutant tumors. The regimen continued to show favorable tolerability and a safety profile consistent with known profiles of the individual drugs. These findings support the ongoing Phase 3 OPERA-02 trial, which is assessing the combination as a frontline therapy in advanced or metastatic breast cancer.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Olema Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9547706-en) on October 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251018:nNDL1WtlKD:1","article_id":"2576095090","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2576095090","pubTimestamp":1760770815,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Olema Pharmaceuticals Inc. has announced updated data from a Phase 1b/2 clinical study evaluating palazestrant  in combination with ribociclib for patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative  advanced or metastatic breast cancer. The results, which will be presented at the European Society for Medical Oncology  Congress 2025 on October 20, showed that the combination demonstrated activity across all dose cohorts and subgroups. The median progression-free survival  was 15.5 months in the 120 mg palazestrant cohort overall. Among patients previously treated with CDK4/6 inhibitors, median PFS was 9.2 months for those with ESR1 wild-type tumors and 13.8 months for those with ESR1 mutant tumors. The regimen continued to show favorable tolerability and a safety profile consistent with known profiles of the individual drugs. These findings support the ongoing Phase 3 OPERA-02 trial, which is assessing the combination as a frontline therapy","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","NDAQ":"纳斯达克OMX交易所","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","OLMA":"Olema Pharmaceuticals, Inc.","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4585":"ETF&股票定投概念","BK4588":"碎股","BK4112":"金融交易所和数据","BK4505":"高瓴资本持仓"},"translate_title":"Olema报告Palazestrant联合Ribociclib治疗晚期乳腺癌的有希望的1b/2期数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OLMA":0.9,"NDAQ":0.9},"content_text":"Olema Reports Promising Phase 1b/2 Data for Palazestrant Plus Ribociclib in Advanced Breast Cancer\n    \n\n        Olema Pharmaceuticals Inc. has announced updated data from a Phase 1b/2 clinical study evaluating palazestrant (OP-1250) in combination with ribociclib for patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. The results, which will be presented at the European Society for Medical Oncology (ESMO) Congress 2025 on October 20, showed that the combination demonstrated activity across all dose cohorts and subgroups. The median progression-free survival $(PFS)$ was 15.5 months in the 120 mg palazestrant cohort overall. Among patients previously treated with CDK4/6 inhibitors, median PFS was 9.2 months for those with ESR1 wild-type tumors and 13.8 months for those with ESR1 mutant tumors. The regimen continued to show favorable tolerability and a safety profile consistent with known profiles of the individual drugs. These findings support the ongoing Phase 3 OPERA-02 trial, which is assessing the combination as a frontline therapy in advanced or metastatic breast cancer.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Olema Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9547706-en) on October 18, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}